ArticleEuropean radiology2026
Combining Node-RADS with ADC can improve diagnostic performance for lymph node metastasis in breast cancer.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
objectivesTo evaluate the diagnostic value of Node Reporting and Data System (Node-RADS) and apparent diffusion coefficient (ADC) values for identifying axillary lymph node metastasis (ALNM) in breast cancer, and to construct and validate a predictive model for ALNM evaluation. MATERIALS AND
methodsThe Node-RADS scores for axillary lymph nodes (ALN) were retrospectively assessed. The ADC values of the corresponding lymph nodes (LN) and the primary tumors were measured to calculate the calibrated ADC (cADC) and relative ADC (rADC) values. A predictive model was developed based on the factors associated with ALNM that were identified in the univariate and multivariate analyses. The model was subsequently validated on an internal and external validation dataset. The diagnostic performance was evaluated using receiver operating characteristic (ROC) curves and the area under the curve (AUC). Cohen's Kappa analysis was used to evaluate inter-reader agreement.
resultsSeven hundred eighty-seven female breast cancer patients from Center 1 (mean age, 52.01 years ± 9.42) and 63 from Center 2 (mean age, 53.21 years ± 11.32) were included. Node-RADS exhibited good diagnostic performance in distinguishing ALNM, with a score greater than 2 being the optimal cutoff value. The model incorporating Node-RADS and cADC showed excellent predictive ability, achieving AUC values of 0.807 (95% CI: 0.751, 0.856) and 0.801 (95% CI: 0.681, 0.891) in the internal and external validation sets, respectively.
conclusionNode-RADS provides a reliable method for the standardized assessment of ALNM. The combination of Node-RADS with ADC improves the diagnostic performance for ALNM in breast cancer. KEY POINTS: Question Axillary lymph node status significantly influences treatment strategies for breast cancer, yet there remains a lack of consensus regarding their radiological evaluation. Findings Both Node-RADS and ADC values are effective for distinguishing lymph node metastasis, and their combination improves the diagnostic performance for ALNM. Clinical relevance The predictive model that integrates Node-RADS and cADC serves as a simple and practical tool to assist clinicians in formulating personalized treatment strategies.
Indexed as
Identifiers
42236540What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.